Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria

被引：26

作者：

Harper P. ^{[1
]}

Wahlin S. ^{[1
]}

机构：

[1] Porphyria Centre Sweden, Department of Laboratory Medicine, Karolinska University Hospital

来源：

Current Treatment Options in Gastroenterology | 2007年 / 10卷 / 6期

关键词：

Porphyrin; Hemin; Porphyria; Porphyria Cutanea Tarda; Acute Intermittent Porphyria;

D O I：

10.1007/s11938-007-0044-9

中图分类号：

学科分类号：

摘要：

The porphyrias are a group of uncommon metabolic diseases caused by enzyme deficiencies within heme biosynthesis that lead to neurotoxic or phototoxic heme precursor accumulation. There are four acute porphyrias characterized by neuropsychiatric symptoms: acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and 5-aminolevulinic acid dehydratase deficiency porphyria. Treatment includes elimination of any porphyrogenic factor and symptomatic treatment. Carbohydrate and intravenous heme administration constitute specific therapies in the disorders' acute phase. The mainstay treatment in the cutaneous porphyrias is avoidance of sunlight exposure. In porphyria cutanea tarda and the two acute porphyrias with skin manifestations, variegate porphyria and hereditary coproporphyria, care of the vulnerable skin is important. In porphyria cutanea tarda, specific treatment is accomplished by a series of phlebotomies and/or by low-dose chloroquine administration. In erythropoietic protoporphyria, light-protective beta-carotene is prescribed. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：444 / 455

页数：11

共 43 条

[1]

Anderson K.E., Sassa S., Bishop D.F., Desnick R.J., Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias, The Metabolic and Molecular Bases of Inherited Disease, pp. 2991-3062, (2001)

[2]

Badminton M.N., Elder G.H., Molecular mechanisms of dominant expression in porphyria, J Inherit Metab Dis, 28, pp. 277-286, (2005)

[3]

Soonawalla Z.F., Orug T., Badminton M.N., Et al., Liver transplantation as a cure for acute intermittent porphyria, Lancet, 363, pp. 705-706, (2004)

[4]

Stojeba N., Meyer C., Jeanpierre C., Et al., Recovery from a variegate porphyria by a liver transplantation, Liver Transpl, 10, pp. 935-938, (2004)

[5]

McGuire B.M., Bonkovsky H.L., Carithers Jr R.L., Et al., Liver transplantation for erythropoietic protoporphyria liver disease, Liver Transpl, 11, pp. 1590-1596, (2005)

[6]

Rand E.B., Bunin N., Cochran W., Et al., Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria, Pediatrics, 118, (2006)

[7]

Wahlin S., Aschan J., Bjornstedt M., Et al., Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis, J Hepatol, 46, pp. 174-179, (2007)

[8]

Deacon A.C., Elder G.H., ACP Best Practice No 165: Front line tests for the investigation of suspected porphyria, J Clin Pathol, 54, pp. 500-507, (2001)

[9]

Andersson C., Innala E., Backstrom T., Acute intermittent porphyria in women: Clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden, J Intern Med, 254, pp. 176-183, (2003)

[10]

Hift R.J., Meissner P.N., An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity, Medicine, 84, pp. 48-60, (2005)

← 1 2 3 4 5 →